The present invention provides a method for preparing a drug composition, which includes steps of dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug into a solvent to form a mixture solution, and the pH value of the mixture solution is adjusted to a range without precipitating the hydrophilic drug(s) and the hydrophobic drug(s), wherein the amphiphilic chitosan derivative is modified by a plurality of hydrophilic group(s) and a plurality of hydrophobic group(s); and after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH value of the mixture solution is between pH 6 to 7. The hydrophilic drug(s) and the hydrophobic drug(s) are encapsulated simultaneously by one-pot synthesis, and the protein could be modified by one-pot synthesis to provide a drug composition with multiple functions.
FIG. 5
DRUG COMPOSITION AND METHOD FOR PREPARING THE SAME

REFERENCE TO RELATED APPLICATION

[0001] This application claims foreign priority under 35 U.S.C. §119(a) to patent application Ser. No. 10/412,4706, filed on Jul. 30, 2015, in the Intellectual Property Office of Ministry of Economic Affairs, Republic of China (Taiwan, R.O.C.), the entire content of the above-referenced application is incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The invention relates to drug compositions and preparation methods thereof and, particularly, to a drug composition encapsulating hydrophobic drug(s) and hydrophilic drug(s) with amphiphilic chitosan, and a method for preparing the same.

BACKGROUND OF THE INVENTION

[0003] Chitin presents broadly in nature, which occurs in crustaceans (such as the exoskeleton of shrimps, crabs and insects), microorganisms (cell wall of bacteria and mycoplasma) and plants such as algae. Chitosan [poly(β-1,4-glucosamine)], also called chitine, is a non-uniform polymeric material formed by various degrees of deacetylation reaction of chitin. Chitosan is a copolymer having N-acetyl glucosamine and N-glucosamine as structural units, and the content of the N-glucosamine structural unit in the copolymer is usually more than 60%. Chitosan becomes an important macromolecular biomedical material due to its advantages of good biocompatibility, non-toxicity, degradability in organisms (by lysozyme), low price, and abundant raw materials without the worries of supply shortage.

[0004] In conventional encapsulating techniques for drug carriers, more than two anticancer drugs (e.g., hydrophilic drugs and hydrophobic drugs) are encapsulated in multiple-shell layers to form nanoparticles. The nanoparticles become multiple-functional for cancer treatment, when they are linked to an antibody/protein/peptide/polysaccharide having specific recognition or with the addition of materials for image development. However, encapsulating two drugs in a manner of multiple-shell layers tends to generate problems, such as leakage of the drugs, poor encapsulating rate, complication of the process, etc. Furthermore, it is difficult to encapsulate hydrophilic and hydrophobic drugs at the same time, if a macromolecule self-assembly manner is utilized to encapsulate drugs.

[0005] Therefore, it is an important issue to resolve the process problems of requiring multiple steps and several environments in conventional nanoparticle encapsulation of multiple drugs by providing a method for encapsulating hydrophilic and hydrophobic drugs synchronously in a single step to prepare drug-carrying particles.

SUMMARY OF THE INVENTION

[0006] The present invention provides a method for preparing a drug composition, which comprises: dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug in a solvent to form a mixture solution, wherein the amphiphilic chitosan derivative was modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups, and the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug; and after stirring the mixture solution for at least 12 hours, receiving the drug composition when pH of the mixture solution is between 6 to 7.

[0007] The present invention further provides a drug composition which includes: an amphiphilic chitosan derivative modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups; at least a hydrophilic drug embedded in the amphiphilic chitosan derivative, and the at least a hydrophilic drug attracts the plurality of hydrophilic groups by electrostatic force; and at least a hydrophobic drug embedded in the amphiphilic chitosan derivative and gathered among the a plurality of hydrophobic groups.

[0008] From the foregoing, in the present invention, a proposal of encapsulating one or more same/different hydrophilic/hydrophobic drugs synchronously is achieved by using an amphiphilic chitosan macromolecular having high biocompatibility as a base and adjusting the solution environment for the macromolecular self-assembly of the amphiphilic chitosan. In addition, the surface of the drug-encapsulating particles is modified by attaching a targeting subject having specific identification capability (such as antibodies) through a cross-linking agent, or alternatively, a compound having image development effect can be encapsulated simultaneously with the drugs, thereby the nanoparticles become medical means with functions of identification, imaging and treatment to poison and kill cancer cells efficiently.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 shows encapsulating rates for Cisplatin (CDDP) and demethoxycurcumin (DMC) of double-drug-encapsulating nanoparticles in solutions at various pH values (pH 7.5, pH 8.5, pH 9.5, pH 10.5 and pH 11).

[0010] FIG. 2 shows encapsulating rates for Cisplatin and demethoxycurcumin of double-drug-encapsulating nanoparticles in solutions at various pH values (pH 8, pH 8.5, and pH 9).

[0011] FIG. 3 shows a transmission electron microscopic image of nanoparticles encapsulating double drugs.

[0012] FIG. 4 shows influences of three different drug/carrier combinations, i.e., free DMC-CDDP combination, CHC/DMC-CDDP nanoparticles and CHC/DMC-CDDP/Anti-CD133 nanoparticles, on cell survival rate.

[0013] FIG. 5 shows influences of CHC/DMC-CDDP nanoparticles and CHC/DMC-CDDP/Anti-CD133 nanoparticles on cell survival rate, wherein X-axis shows contents of DMC and CDDP in the nanoparticles.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The implementation of the present invention will be illustrated by the particular embodiments below; a person skilled in the art can readily understand the advantages and effects of the present invention by the content disclosed by the present specification. The present invention also can be performed or applied by other different modes, and details of the present specification also can be modified or altered based on various views or applications without departing from the spirit described in the present invention.

[0015] As used in the specification, the term "one-pot synthesis" means a method, in which reactant (e.g., amphiphilic chitosan) is allowed to encapsulate hydrophilic and hydrophobic drugs in one self-assembly reaction to improve
reaction efficiency. The method can eliminate the lengthy processes for isolation and post-purification treatment, thereby shortening time, saving resources and improving efficiency.

[0016] The present invention provides a preparation method of a drug composition, which includes: dispersing an amphiphilic chitosan derivative, at least one hydrophobic drugs, and at least one hydrophilic drugs in a solvent such as water to form a mixture solution, wherein the amphiphilic chitosan derivative was modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups, and the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug; and after stirring the mixture solution for 12 hours, receiving the drug composition when pH of the mixture solution is between 6 to 7.

[0017] According to an embodiment of the present invention, the mixture solution was stirred for 12 to 24 hours.

[0018] According to an embodiment of the present invention, in the preparation method of the present invention, weight percentages range of the amphiphilic chitosan derivative is 0.01 wt % to 2 wt %, the concentration of the hydrophobic drug used is in a range of more than 0 to 3 mM, and the concentration of the hydrophilic drug used is in a range of more than 0 to 3 mM.

[0019] The hydroxyl group (—OH) and the amino group (—NH₂) on chitosan are sites which can be modified very easily. In general, chitosan is used as a backbone, and its hydroxyl terminal is modified to be hydrophilic, and its amino terminal is modified to be hydrophobic. The modification methods will not be detailed since they are well known.

[0020] In an Example of the foregoing preparation method, pH of the mixture solution is adjusted to a range in which the hydrophilic drug and the hydrophobic drug will not precipitate. In general, the mixture solution is adjusted to be weakly basic, specifically, by adding aqueous alkaline solution, i.e., adding an aqueous alkaline solution with pH above 8, for example, pH of 8.5 to 12.5, with pH of 9 to 10 being preferable, thereby, pH of the mixture solution is adjusted to a range in which the hydrophilic drug and the hydrophobic drug will not precipitate.

[0021] In an Example of the foregoing preparation method, first, a hydrophobic drug is added to an aqueous solution of amphiphilic chitosan derivative, then an aqueous alkaline solution is added thereeto, at last, a hydrophilic drug is added, and pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug, wherein, the pH of the aqueous alkaline solution is in a range of 8.5 to 12.5 with pH of 9.0 to 10.0 being preferable.

[0022] Adjusting the mixture solution to be alkaline or adding a base can allow the H⁺ of a hydrophilic group on the biologic structure of the amphiphilic chitosan derivative to be released, and the hydrophilic group on the biologic structure of the amphiphilic chitosan derivative (such as COO⁻) will attract and conjugate a positively charged drug (such as Cisplatin, a hydrophilic drug) due to electrostatic force; and at the same time, since the hydrophilic drug is attracted by the electrostatic force, in contrast, a hydrophobic drug (such as demethoxyureaurein) will be encapsulated by hydrophobic groups (such as caproyl groups) on the biologic structure of the amphiphilic chitosan derivative; finally, a drug composition in the form of a plurality of particles is formed according to the self-assembly reaction.

[0023] After completing the encapsulation of drugs, the entire solution has a pH value of 6 to 7, with pH 6.7 being preferable, and the prepared drug-carrier particles are neutral and can be used without further neutralization reaction or purification step. According to an embodiment of the present invention, the drug composition is in the form of a plurality of particles. Additionally, the preparation method of the present invention further includes connecting a targeting subject to the surface of the plurality of particles using a cross-linking agent. In non-limiting Examples, the targeting subject is at least one selected from the group consisting of an antibody, a peptide and a protein.

[0024] In an embodiment, the cross-linking agent is at least one compound selected from the group consisting of 1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide.

[0025] According to an embodiment of the preparation method of the present invention, the method further includes dispersing an image developing compound in the solution, wherein the image developing compound is a fluorescent compound or an organometallic developer.

[0026] According to an embodiment of the present invention, the amphiphilic chitosan derivative has a plurality of repeating units of the structure in formula (I) below:

\[
\begin{align*}
\text{CH}_{3} \text{OR}_{1} & \\
\text{OH} & \\
\text{NHR}_{2} & \\
\end{align*}
\]

[0027] wherein, each R₁ is independently hydrogen, a C₁ to C₄ alkyl or a C₁ to C₆ carboxyl, each R₂ is independently hydrogen, a C₁ to C₁₂ alkyl, a C₁ to C₆ carboxyl or a C₂ to C₁₂ acyl, and m is an integer between 100 to 2000.

[0028] wherein, the number of the repeating units having a R₁ selected from a C₁ to C₄ alkyl and a C₁ to C₆ carboxyl is 20 to 2000; and the number of the repeating units having a R₂ selected from a C₁ to C₁₂ alkyl, a C₁ to C₆ carboxyl or a C₂ to C₁₂ acyl is 20 to 2000.

[0029] According to an embodiment of the present invention, the chitosan derivative used in the present invention is showed in formula (II) below:
[0030] wherein, each $R_3$ is independently a C5-C11 alkyl, and each of x, y, z, n and p is independently an integer between 20 to 2,000.

[0031] According to an embodiment of the present invention, the hydrophobic drug used in the present invention is at least one selected from, but not limited to, the group consisting of Taxol, camptothecin, demethoxycurcumin (DMC), Topotecan, Cyclosporine A, Epirubicin and Rapamycin.

[0032] According to an embodiment of the present invention, the hydrophilic drug used in the present invention is at least one selected from, but not limited to, the group consisting of Cisplatin (CDDP), Doxorubicin, Oxaliplatin, Carboplatin, Nedaplatin and Satraplatin.

[0033] The present invention further provides a drug composition which includes: an amphiphilic chitosan derivative modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups; at least one hydrophilic drug embedded in the amphiphilic chitosan derivative, and the at least one hydrophilic drug attracts the a plurality of hydrophilic groups via electrostatic force; and at least one hydrophobic drug embedded in the amphiphilic chitosan derivative and gathered among the a plurality of hydrophobic groups.

[0034] According to an embodiment of the present invention, the drug composition is in the form of a plurality of particles. According to another embodiment of the present invention, the plurality of particles has a size in a range of 50 nm to 300 nm.

[0035] According to an embodiment of the present invention, the drug composition of the present invention is used for inhibiting the growth of cancer cells, wherein it is used for inhibiting the growth of at least one kind of cancer cells selected from the group consisting of non-small cell lung cancer cells, ovarian cancer cells, testicular cancer cells, bladder cancer cells, cervical cancer cells and lung cancer cells.

[0036] According to an embodiment of the present invention, the solvent and water can be removed from the drug composition of the present invention by means of lyophilization, concentration under reduced pressure, and vacuum drying.

[0037] The present invention will be further detailed with the Examples below, and it should be understood that the Examples is for illustration only but not for limiting the implementation of the present invention.

**EXAMPLES**

**Preparation of Amphiphilic Chitosan Derivatives Modified with Hydrophobic Caproyl and Hydrophilic Carboxymethyl**

[0038] First, 5 g of chitosan (Mw=215,000 g/mol, deacetyl degree of 80 to 90%, purchased from Adrich-Sigma) was suspended in isopropanol (50 mL) at room temperature, and the mixture was stirred for 30 minutes. The obtained suspension was mixed slowly with aqueous sodium hydroxide solution (12.5 mL) to form a mixture solution, and the grafting amount of hydrophilic functional groups was controlled by adjusting the concentration of sodium hydroxide in the mixture solution. Herein, the mixture solution contains 13.3 M of sodium hydroxide. Next, the mixture solution was allowed to react with chloroacetic acid to prepare a water-soluble hydrophilic carboxymethyl-modified chitosan which was then dried.

[0039] 2 g of dried hydrophilic carboxymethyl-modified chitosan was dissolved in pure water (50 mL) and the solution was stirred for 24 hours. Next, the obtained solution was mixed with methanol (50 mL), and 0.2 M of caproic anhydride was added thereto. After reacting at room temperature for 20 hours, the reaction solution was collected and was dialyzed with aqueous ethanol solution (25% v/v) for 24 hours, then the product was collected after drying to obtain both hydrophobic caproyl-modified and hydrophilic carboxymethyl-modified amphiphilic chitosan derivative with a structure as shown by formula (II) below. Meanwhile, $^1$H NMR spectrum and elemental analysis for N content were performed to determine the sites of substituents and caproyl grafting amount in the chitosan derivative. In this Example, grafting amount of caproyl is 13%.
Example 2

Encapsulating Drugs Using an Amphiphilic Chitosan Derivative

0.5 mg of amphiphilic chitosan powder prepared in Example 1 was weighed and added to 200 µL of 0.1% demethoxycurcumin (in methanol), the mixture was mixed for a while using a shaker, 540 µL of double-distilled water was added thereto following by 60 µL of double-distilled water with pH 10.5, and 200 µL of 0.1% Cisplatin (in water) was added finally, and the mixture was stirred for 12 hours to prepare nanoparticles encapsulating double drugs (containing demethoxycurcumin and Cisplatin).

Example 3

Test for Encapsulating Rate of Drugs in Nanoparticles Encapsulating Double Drugs

The synthesized nanoparticles encapsulating double drugs were placed in a concentrating centrifuge tube, and perform centrifugation at a speed of 4,000 rpm for 30 minutes.

(1). Encapsulating Rate of Cisplatin

The clear solution in the concentrating centrifuge tube was diluted 20 folds and mixed with 0.14% solution of o-phenylenediamine in dimethylformamide at a ratio of 1:1, the mixture was heated at 100°C for 30 minutes and then was cooled in a refrigerator at -20°C for 10 minutes, finally, the solution was examined for the peak value at a wavelength of 705 nm with UV-visual spectrum, and content of non-encapsulated Cisplatin was converted from the peak value, thereby giving the encapsulating rate of Cisplatin.

(2). Encapsulating Rate Test of Demethoxycurcumin

The nanoparticles on the filter membrane of the concentrating centrifuge tube were re-dissolved in double-distilled water, the solution was mixed with methanol at a ratio of 1:1, and the mixture was analyzed using HPLC. The determination was performed at a flow rate of 1 mL/min under the detection condition at a wavelength of 425 nm, using C18 as stationary phase and acetonitrile-0.3% FA (50:50, v/v) as mobile phase, and the detection result was converted into the concentration of demethoxycurcumin to obtain the encapsulating rate of the drug.

0.01% 50 µL of cross-linking agent were added into the solution of nanoparticles encapsulating double drugs, the mixture was stirred for 5 hours to connect the antibody to the surface of the nanoparticles encapsulating double drugs described above, and the prepared nanoparticles encapsulating double drugs have diameter of 190 nm. The diameters and zeta potential of amphiphilic chitosan nanoparticles (hereinafter referred as CHC), nanoparticles encapsulating double drugs (hereinafter referred as CHC/DMC-CDDP), and antibody-conjugated nanoparticles encapsulating double drugs (hereinafter referred as CHC/DMC-CDDP-antibody) are shown in Table 1.

Example 4

Conjugating an Antibody to the Nanoparticles Encapsulating Double Drugs

A proper amount of antibody (anti-CD133) and 0.01% 50 µL of cross-linking agent were added into the solution of nanoparticles encapsulating double drugs, the mixture was stirred for 5 hours to connect the antibody to the surface of the nanoparticles encapsulating double drugs described above, and the prepared nanoparticles encapsulating double drugs have diameter of 190 nm. The diameters and zeta potential of amphiphilic chitosan nanoparticles (hereinafter referred as CHC), nanoparticles encapsulating double drugs (hereinafter referred as CHC/DMC-CDDP), and antibody-conjugated nanoparticles encapsulating double drugs (hereinafter referred as CHC/DMC-CDDP-antibody) are shown in Table 1.

As shown in FIG. 3, the antibody-conjugated nanoparticles encapsulating double drugs were further observed through emission electron microscope.
TABLE 1

Diameters and zeta potentials of various nanoparticles of the present invention

<table>
<thead>
<tr>
<th>Sample name</th>
<th>Diameter (nnm)</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHC</td>
<td>55 ± 2.3</td>
<td>-22.5 ± 0.91</td>
</tr>
<tr>
<td>CHC/DMC-CDDP</td>
<td>140 ± 7.3</td>
<td>-13.0 ± 3.5</td>
</tr>
<tr>
<td>CHC/DMC-CDDP-Antibody</td>
<td>100 ± 6.1</td>
<td>-5.1 ± 0.6</td>
</tr>
</tbody>
</table>

Example 5

Test for Cells Survival Rate in Poisoning and Killing Cancer Cells with CHC/DMC-CDDP and CHC/DMC-CDDP-Antibody Nanoparticles of the Present Invention

[0050] Lung cancer stem cells (A549-ON) were cultured in 24-well plate at 1x10⁶ cells per well, various amounts of formulated free DMC-CDDP combination (free drug) (from left to right in FIG. 4, the amounts were 3.25-75 g/ml, 7.5-150 g/ml, 7.5-300 g/ml, 15-300 g/ml and 20-600 g/ml), CHC/DMC-CDDP nanoparticles (from left to right in FIG. 4, the amounts were 1.25-95 g/ml, 3-125 g/ml, 5-200 g/ml, 6-250 g/ml and 9-265 g/ml) and CHC/DMC-CDDP/anti-CD133 nanoparticles (from left to right in FIG. 4, the amounts were 1.25-95 g/ml, 3-125 g/ml, 5-200 g/ml, 6-250 g/ml and 9-265 g/ml) were applied to the lung cancer stem cells, after culturing for 24 hours, the cells were analyzed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (hereinafter referred as MTT) for cells survival rate. FIG. 4 shows effects of 3 kinds of different drug/canrier combination on the cell survival rate. As shown in FIG. 4, Y-axis is combination index (hereinafter referred as CI), the CI value of less than 1 represents the occurrence of synergistic effect; Fa represents cell apoptosis rate, and the closer to 1 the Fa value is, the higher cell apoptosis rate occurs, which represents better poisoning and killing effects on cancer cells. It can be seen in FIG. 4, drugs without being encapsulated in CHC (i.e., free DMC-CDDP combination) has no synergistic effect, since poisoning and killing effects on cancer cells cannot be enhanced by using double drugs at the same time; the double drugs encapsulated with CHC have clearly synergistic effects at certain amounts (CHC/DMC-CDDP: 6-250 g/ml and 9-265 g/ml; CHC/DMC-CDDP/anti-CD133: 5-200 g/ml, 6-250 g/ml and 9-265 g/ml) and provide good poisoning and killing effects on cancer cells. FIG. 5 shows effects of CHC/DMC-CDDP nanoparticles and CHC/DMC-CDDP/anti-CD133 nanoparticles on cell survival rate, i.e., effects of nanoparticles formed by CHC encapsulating double drugs with/ without conjugating an antibody on poisoning and killing lung cancer stem cells. As shown in FIG. 5, using CHC/DMC-CDDP/anti-CD133 nanoparticles (antibody-conjugated) can effectively reduce survival rate of lung cancer stem cells.

[0051] The foregoing Examples are used for the purpose of illustrating the mechanism and effects only rather than limiting the present invention. Anyone skilled in the art can modify and alter the above Examples without departing from the spirit and scope of the present invention. Therefore, all modifications and alternations made by those skilled in the art on the basis of technical mechanism without departing from the spirit of the present invention should encompassed in the range of the accompanying Claims.

1. A preparation method of a drug composition, comprising:
   - dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug in an solvent to form a mixture solution, wherein the amphiphilic chitosan derivative is modified with a plurality of hydrophobic groups and a plurality of hydrophilic groups, and the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug; and
   - after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH of the mixture solution is between 6 to 7.

2. The preparation method of claim 1, wherein, by adding an aqueous solution with pH of 8.5 to 12.5, the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug.

3. The preparation method of claim 2, wherein, by adding an aqueous solution with pH of 9.0 to 10.5, the pH of the mixture solution is adjusted to a range without precipitating the hydrophilic drug and the hydrophobic drug.

4. The preparation method of claim 1, wherein the drug composition is in the form of a plurality of particles.

5. The preparation method of claim 4, further comprising coupling a targeting subject to surfaces of the plurality of particles via using a cross-linking agent.

6. The preparation method of claim 5, wherein the targeting subject is at least one selected from the group consisting of an antibody, a peptide and a protein.

7. The preparation method of claim 1, further comprising dispersing an image developing compound in the solution.

8. The preparation method of claim 7, wherein the image developing compound is a fluorescent compound or an organometallic developer.

9. A drug composition comprising:
   - an amphiphilic chitosan derivative modified with a plurality of hydrophilic groups and a plurality of hydrophobic groups;
   - at least a hydrophilic drug embedded in the amphiphilic chitosan derivative, and the at least a hydrophilic drug attracting the plurality of hydrophilic groups by electrostatic force, wherein the hydrophilic drug is at least one selected from the group consisting of Cisplatin (CDDP), Doxorubicin, Oxaliplatin, Carboplatin, Nedaplatin and Satraplatin; and
   - at least a hydrophobic drug embedded in the amphiphilic chitosan derivative and gathered among the plurality of hydrophilic groups, wherein the hydrophobic drug is at least one selected from the group consisting of Taxol, camptothecin, demethoxycurcumin (DMC), Topotecan, Cyclosporine A, Epirubicin and Rapamycin.

10. The drug composition of claim 9, wherein the drug composition is in the form of a plurality of particles.

11. The drug composition of claim 10, further comprising a cross-linking agent for a targeting subject coupled to surfaces of the plurality of particles via the cross-linking agent.

12. The drug composition of claim 11, wherein the targeting subject is at least one selected from the group consisting of an antibody, a peptide and a protein.
13. The drug composition of claim 10, wherein the particle size of the plurality of particles is in a range of from 50 nm to 300 nm.

14. The drug composition of claim 9, which is used for inhibiting growth of cancer cells.

15. The drug composition of claim 14, which is used for inhibiting the growth of at least one kind of cancer cells selected from the group consisting of non-small cell lung cancer cells, ovarian cancer cells, testicular cancer cells, bladder cancer cells, cervical cancer cells and lung cancer cells.